736 related articles for article (PubMed ID: 26941338)
1. Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance.
Tjong FV; Brouwer TF; Smeding L; Kooiman KM; de Groot JR; Ligon D; Sanghera R; Schalij MJ; Wilde AA; Knops RE
Europace; 2016 Nov; 18(11):1740-1747. PubMed ID: 26941338
[TBL] [Abstract][Full Text] [Related]
2. Acute and 3-Month Performance of a Communicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator.
Tjong FVY; Brouwer TF; Koop B; Soltis B; Shuros A; Schmidt B; Swackhamer B; Quast AEB; Wilde AAM; Burke MC; Knops RE
JACC Clin Electrophysiol; 2017 Dec; 3(13):1487-1498. PubMed ID: 29759829
[TBL] [Abstract][Full Text] [Related]
3. Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication.
Quast ABE; Tjong FVY; Koop BE; Wilde AAM; Knops RE; Burke MC
Europace; 2018 Nov; 20(11):1866-1871. PubMed ID: 29462311
[TBL] [Abstract][Full Text] [Related]
4. Totally Leadless Dual-Device Implantation for Combined Spontaneous Ventricular Tachycardia Defibrillation and Pacemaker Function: A First Report.
Ahmed FZ; Cunnington C; Motwani M; Zaidi AM
Can J Cardiol; 2017 Aug; 33(8):1066.e5-1066.e7. PubMed ID: 28754393
[TBL] [Abstract][Full Text] [Related]
5. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
[TBL] [Abstract][Full Text] [Related]
6. Combination of a leadless pacemaker and subcutaneous defibrillator with nine effective shock treatments during follow-up of 18 months.
Ljungström E; Brandt J; Mörtsell D; Borgquist R; Wang L
J Electrocardiol; 2019; 56():1-3. PubMed ID: 31226509
[TBL] [Abstract][Full Text] [Related]
7. Long-term performance of a novel communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study.
Breeman KTN; Swackhamer B; Brisben AJ; Quast ABE; Carter N; Shuros A; Soltis B; Koop BE; Burke MC; Wilde AAM; Tjong FVY; Knops RE
Heart Rhythm; 2022 May; 19(5):837-846. PubMed ID: 35066181
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices.
Kuschyk J; Stach K; Tülümen E; Rudic B; Liebe V; Schimpf R; Borggrefe M; Röger S
Heart Rhythm; 2015 Nov; 12(11):2230-8. PubMed ID: 26073595
[TBL] [Abstract][Full Text] [Related]
10. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Use of the Subcutaneous Implantable Cardioverter Defibrillator and a Permanent Pacemaker.
Huang J; Patton KK; Prutkin JM
Pacing Clin Electrophysiol; 2016 Nov; 39(11):1240-1245. PubMed ID: 27734502
[TBL] [Abstract][Full Text] [Related]
12. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application.
Manegold JC; Israel CW; Ehrlich JR; Duray G; Pajitnev D; Wegener FT; Hohnloser SH
Eur Heart J; 2007 Jul; 28(14):1731-8. PubMed ID: 17569681
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial.
Knops RE; van der Stuijt W; Delnoy PPHM; Boersma LVA; Kuschyk J; El-Chami MF; Bonnemeier H; Behr ER; Brouwer TF; Kääb S; Mittal S; Quast ABE; Smeding L; Tijssen JGP; Bijsterveld NR; Richter S; Brouwer MA; de Groot JR; Kooiman KM; Lambiase PD; Neuzil P; Vernooy K; Alings M; Betts TR; Bracke FALE; Burke MC; de Jong JSSG; Wright DJ; Jansen WPJ; Whinnet ZI; Nordbeck P; Knaut M; Philbert BT; van Opstal JM; Chicos AB; Allaart CP; Borger van der Burg AE; Clancy JF; Dizon JM; Miller MA; Nemirovsky D; Surber R; Upadhyay GA; Weiss R; de Weger A; Wilde AAM; Olde Nordkamp LRA;
Circulation; 2022 Feb; 145(5):321-329. PubMed ID: 34779221
[TBL] [Abstract][Full Text] [Related]
15. Electrical cardioversion of patients with implanted pacemaker or cardioverter-defibrillator: results of a survey of german centers and systematic review of the literature.
Lüker J; Sultan A; Plenge T; van den Bruck J; Heeger CH; Meyer S; Mischke K; Tilz RR; Vollmann D; Nölker G; Schäffer B; Willems S; Steven D
Clin Res Cardiol; 2018 Mar; 107(3):249-258. PubMed ID: 29151182
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Leadless Pacemaker and Subcutaneous ICD Implantation With Intraoperative Screening: Workflow in Two Patients.
Nieves J; Laslett DB; Basil A; Whitman IR; Cooper JM; Cronin EM
JACC Case Rep; 2022 Dec; 4(23):101535. PubMed ID: 36507298
[TBL] [Abstract][Full Text] [Related]
17. Defibrillation testing is mandatory in patients with subcutaneous implantable cardioverter-defibrillator to confirm appropriate ventricular fibrillation detection.
le Polain de Waroux JB; Ploux S; Mondoly P; Eschalier R; Strik M; Houard L; Pierre B; Buliard S; Klotz N; Ritter P; Haissaguerre M; Mahfouz K; Bordachar P
Heart Rhythm; 2018 May; 15(5):642-650. PubMed ID: 29709229
[TBL] [Abstract][Full Text] [Related]
18. [The concurrent implantation of a last-generation automatic defibrillator and a 2-chamber pacemaker].
Cesario AS; Palermo P; Baragli D; Amici E; Biancalana G; Gambelli G; Neri R
G Ital Cardiol; 1998 Aug; 28(8):878-86. PubMed ID: 9773313
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study.
Gold MR; Theuns DA; Knight BP; Sturdivant JL; Sanghera R; Ellenbogen KA; Wood MA; Burke MC
J Cardiovasc Electrophysiol; 2012 Apr; 23(4):359-66. PubMed ID: 22035049
[TBL] [Abstract][Full Text] [Related]
20. Combined third-generation implantable cardioverter defibrillator with permanent unipolar pacemakers: preliminary observations.
Haffajee C; Casavant D; Desai P; Moon R; Voukydis P; Pacetti P
Pacing Clin Electrophysiol; 1996 Feb; 19(2):136-42. PubMed ID: 8834682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
